BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alimatravir readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alimatravir\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07600775-1010@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Alimatravir: Phase 1 readout est. (NCT07600775)
DESCRIPTION:Alimatravir\, phase 1\, HIV.\nStudy: A Clinical Trial of MK-852
 7 and Rifampin in Adult Participants With Latent Tuberculosis Infection (M
 K-8527-019)\nEstimated primary completion: 19 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/alimatravir#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07600775
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044297-1010@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07044297)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Clinical Study of MK-852
 7 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)\nEs
 timated primary completion: 22 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07044297
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071623-1010@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07071623)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Study of MK-8527 to Prev
 ent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)\nEstimated p
 rimary completion: 18 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07071623
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850609-1010@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Alimatravir: Phase 2 readout est. (NCT07850609)
DESCRIPTION:Alimatravir\, phase 2\, HIV.\nStudy: A Clinical Study of Alimat
 ravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on G
 ender-affirming Hormone Therapy and at Low Likelihood of Human Immunodefic
 iency Virus (HIV)-1 Exposure (MK-8527-018)\nEstimated primary completion: 
 2 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alim
 atravir#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07850609
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
